Your browser is no longer supported. Please, upgrade your browser.
EDIT Editas Medicine, Inc. monthly Stock Chart
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own0.10% Shs Outstand62.14M Perf Week7.64%
Market Cap1.79B Forward P/E- EPS next Y-3.32 Insider Trans-32.69% Shs Float61.48M Perf Month-6.72%
Income-91.20M PEG- EPS next Q-0.75 Inst Own82.80% Short Float18.31% Perf Quarter-13.17%
Sales91.60M P/S19.56 EPS this Y-14.60% Inst Trans1.93% Short Ratio12.62 Perf Half Y8.40%
Book/sh7.10 P/B4.31 EPS next Y-94.20% ROA-16.40% Target Price38.00 Perf Year1.02%
Cash/sh8.46 P/C3.62 EPS next 5Y- ROE-26.70% 52W Range14.01 - 39.96 Perf YTD3.31%
Dividend- P/FCF- EPS past 5Y-46.80% ROI-53.70% 52W High-23.45% Beta1.78
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low118.34% ATR1.78
Employees208 Current Ratio9.20 Sales Q/Q1533.10% Oper. Margin- RSI (14)54.43 Volatility5.35% 6.32%
OptionableYes Debt/Eq0.00 EPS Q/Q118.90% Profit Margin-99.60% Rel Volume1.29 Prev Close31.34
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume891.45K Price30.59
Recom2.70 SMA203.60% SMA500.12% SMA2007.79% Volume1,139,456 Change-2.39%
Nov-03-20Initiated Robert W. Baird Underperform $14
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Nov-10-20 04:01PM  
Nov-09-20 04:05PM  
Nov-07-20 09:06AM  
Nov-06-20 03:30PM  
Nov-05-20 05:25PM  
Nov-02-20 10:31AM  
Oct-29-20 04:01PM  
Oct-21-20 10:23AM  
Oct-13-20 09:45AM  
Oct-12-20 09:45AM  
Oct-10-20 09:55AM  
Oct-07-20 10:04AM  
Oct-06-20 07:45PM  
Sep-30-20 06:45AM  
Sep-18-20 06:43PM  
Sep-11-20 07:00AM  
Sep-05-20 11:32AM  
Sep-04-20 08:00AM  
Aug-26-20 11:54AM  
Aug-25-20 11:54AM  
Aug-24-20 08:30AM  
Aug-10-20 11:54AM  
Aug-06-20 04:05PM  
Jul-30-20 12:33PM  
Jul-29-20 08:00AM  
Jul-27-20 04:01PM  
Jul-25-20 11:52AM  
Jul-23-20 04:01PM  
Jul-21-20 07:07AM  
Jul-12-20 08:45AM  
Jul-09-20 07:31AM  
Jul-07-20 09:00AM  
Jul-02-20 11:32AM  
Jun-27-20 10:20PM  
Jun-26-20 04:05PM  
Jun-24-20 05:12AM  
Jun-23-20 09:48PM  
Jun-19-20 08:41AM  
Jun-12-20 06:00AM  
Jun-06-20 11:31AM  
Jun-04-20 08:13AM  
Jun-03-20 07:02AM  
May-29-20 12:00PM  
May-23-20 07:28AM  
May-22-20 07:39AM  
May-18-20 06:21PM  
May-15-20 09:20AM  
May-10-20 09:28AM  
May-08-20 12:38PM  
May-07-20 10:15AM  
May-04-20 08:25AM  
Apr-30-20 08:05AM  
Apr-29-20 09:00AM  
Apr-28-20 12:33PM  
Apr-06-20 08:59AM  
Mar-27-20 11:31AM  
Mar-19-20 10:40AM  
Mar-11-20 09:20PM  
Mar-05-20 08:29AM  
Mar-04-20 05:00AM  
Feb-28-20 09:06AM  
Feb-27-20 02:56PM  
Feb-26-20 05:25PM  
Feb-19-20 04:02PM  
Feb-17-20 07:12AM  
Feb-06-20 12:30PM  
Feb-03-20 11:27AM  
Jan-17-20 02:09PM  
Jan-13-20 09:00AM  
Jan-10-20 04:30PM  
Jan-09-20 09:00AM  
Jan-06-20 11:00PM  
Jan-02-20 09:00AM  
Dec-30-19 04:07PM  
Dec-24-19 12:00PM  
Dec-19-19 09:15AM  
Dec-14-19 08:42PM  
Dec-12-19 11:30AM  
Dec-09-19 06:00PM  
Dec-03-19 01:03AM  
Dec-02-19 11:43AM  
Nov-20-19 09:41AM  
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albright CharlesEVP/Chief Scientific OfficerNov 09Sale31.212287,11624,907Nov 10 04:13 PM
Albright CharlesEVP/Chief Scientific OfficerOct 15Sale31.393,00094,17025,135Oct 16 04:38 PM
Collins CynthiaCEOAug 20Sale36.661,97672,44045,022Aug 21 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Option Exercise16.5110,000165,10038,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 17Sale35.2910,000352,90028,135Aug 19 04:44 PM
Albright CharlesEVP/Chief Scientific OfficerAug 07Sale34.992388,32828,135Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Option Exercise16.5110,000165,10038,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerAug 06Sale37.4710,000374,70028,373Aug 10 04:24 PM
Albright CharlesEVP/Chief Scientific OfficerJul 15Sale32.223,00096,66028,373Jul 17 05:32 PM
Albright CharlesEVP/Chief Scientific OfficerMay 06Sale25.281513,81731,373May 08 04:17 PM
Albright CharlesChief Scientific OfficerFeb 07Sale26.9562216,76331,524Feb 10 04:34 PM
Albright CharlesChief Scientific OfficerFeb 03Sale26.545,549147,28820,553Feb 04 05:24 PM
Albright CharlesChief Scientific OfficerJan 31Option Exercise0.0017,977026,102Feb 04 05:24 PM